Nestlé announces the successful completion of its acquisition of Aimmune Therapeutics Inc.  

Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc's global pharmaceutical business.

"Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives,” said Greg Behar, CEO of NHSc. "Aimmune's Palforzia, the first medication approved for treating peanut allergy, is a game-changer and it's only the beginning. Aimmune's pharmaceutical expertise and infrastructure will complement our existing research and development to further drive growth globally."

Aimmune will continue to be run from Brisbane, CA. Andrew Oxtoby has been named as Aimmune's president & CEO, along with a new executive leadership team. Oxtoby was previously Aimmune's chief commercial officer.